文献速递心外重症与机械循环支持

左心室辅助装置更换术后的结局分析

Outcome after left ventricular assist device exchange.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

以HeartWare作为初始装置的患者右心衰竭和呼吸衰竭风险较高。

要点

  • LVAD更换术后短期最常见并发症为肺部感染和右心衰竭,各占16.3%。
  • 长期最常见并发症为出口部位感染(34.7%)和设备故障(25.3%)。
  • 以HeartWare作为初始装置者右心衰竭和呼吸衰竭风险较高。

核心结论

  • LVAD更换术死亡率相对较低,但术后其他不良事件常见。
  • 以HeartWare心室辅助装置作为初始装置的患者在更换术后可能面临更高的右心衰竭和呼吸衰竭风险。

研究设计与样本

  • 使用Logistic回归和Cox回归分析分别识别短期和长期不良事件的潜在危险因素。
  • 采用Kaplan-Meier估计评估更换术后生存率。

主要发现

  • 短期最常见并发症为肺部感染(16.3%)和右心衰竭(16.3%)。
  • 长期最常见并发症为出口部位感染(34.7%)和设备故障(25.3%)。
  • 以HeartWare作为初始装置者右心衰竭风险高于HeartMate II和HeartMate 3(HR 6.42,95%CI 1.80-22.90)。
  • 以HeartWare作为初始装置者呼吸衰竭风险高于HeartMate II和HeartMate 3(HR 7.81,95%CI 1.95-31.23)。

关键数值与推荐

  • 更换术后1年生存率为83%(95%CI 75.5-95.3%)。
  • 更换术后6年生存率为67%(95%CI 53.9-84.7%)。
  • 更换术后5年时,25.0%的患者接受了心脏移植,23.8%接受了再次更换,32.5%存活且未接受新干预。

临床怎么用

  • LVAD更换术后应关注短期肺部感染和右心衰竭的发生。
  • 长期随访中需注意出口部位感染和设备故障。
  • 对于以HeartWare作为初始装置的患者,更换术后应警惕右心衰竭和呼吸衰竭风险。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Left ventricular assist device (LVAD) therapy has evolved from a short-term bridge-to-transplant strategy into a long-term and often chronic therapy due to long waiting times for heart transplantation and application as destination therapy. Consequently, patients are at risk of developing complications necessitating LVAD exchange. The aim of this study is to assess patient outcomes after LVAD exchange. METHODS: Patients who underwent LVAD exchange between January 2010 and December 2022 were included. Logistic and cox regression analyses were used to identify potential risk factors for short and long-term adverse events, respectively. Survival after exchange was assessed using Kaplan-Meier estimates. RESULTS: Sixty-one patients underwent a total of 80 LVAD exchanges. Most frequently observed short-term complications were pulmonary infections (16.3%) and right heart failure (16.3%). Exit-site infections (34.7%) and device malfunctions (25.3%) were the most often observed long-term complications. HeartWare ventricular assist device as index device was associated with a higher risk of right heart failure [hazard ratio 6.42, 95% confidence interval (CI) 1.80-22.90] and respiratory failure (hazard ratio 7.81, 95% CI 1.95-31.23) compared to HeartMate II and HeartMate 3. Survival was 83% (95% CI 75.5-95.3%) at 1 year and 67% (95% CI 53.9-84.7%) at 6 years after exchange. After 5 years, 25.0% was transplanted, 23.8% had undergone a re-exchange and 32.5% was alive without new intervention. CONCLUSIONS: Although LVAD exchange can be performed with a relatively low mortality, other post-operative adverse events are common. Patients with the HeartWare ventricular assist device as index device may be at higher risk of developing right heart failure and respiratory failure after exchange.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Niamat J, Ramjankhan F, Van Der Kaaij N, et al. Outcome after left ventricular assist device exchange. Eur J Cardiothorac Surg. 2024. PMID: 39235928. doi:10.1093/ejcts/ezae317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。